BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women’s healthcare company, today announced two new strategic hires: Dawn Halkuff as Chief Commercial Officer and Yulii Bogatyrenko as Senior Vice President of Business Development. Both executives bring women’s health experience and relevant skills to the company in advance of the potential launch of its first bio-identical hormone therapy drug candidate in the second half of 2017.
“We are extremely pleased that Dawn and Yulii are joining our executive team, bringing key commercial and business development capabilities to our company, and strengthening our overall women’s health expertise,” said TherapeuticsMD CEO Robert G. Finizio. “Dawn is a proven women’s health expert with commercial, sales and marketing experience specific to post-menopausal women, and she has a sophisticated understanding of how to motivate women and healthcare professionals. Yulii has tremendous long-term relationships both internationally and domestically in the pharmaceutical industry. We believe that these two seasoned professionals will help us successfully launch our advanced hormone therapy products, if approved.”
Dawn Halkuff has held numerous senior level positions over 20 years of commercial and marketing experience. She was previously at Pfizer, Inc. (NYSE: PFE), where she held various leadership roles in women’s health since 2010. Most recently, she was Senior Vice President of the Pfizer Consumer Healthcare Wellness Organization and a member of the Consumer Global Leadership Team. Prior to that, Ms. Halkuff was commercial lead for sales and marketing of the Pfizer Women’s Health Division, focusing on the company’s reinvestment in hormone therapy treatment, including Premarin Vaginal Cream® and oral hot flash treatments. From 2005 to 2010, Ms. Halkuff was Head of Global Innovation at Weight Watchers International (NYSE: WTW), where she created new weight-loss products, services, and solutions for women worldwide. She holds a BS in Psychology from University of Connecticut and an MBA from Pennsylvania State University.
Yulii Bogatyrenko has over 20 years of experience in biopharmaceutical and consumer businesses, with extensive experience in women’s health. Most recently, he was Senior Vice President of Business Development at Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), where he developed global and regional partnerships for the company’s anti-infective products and led the company’s U.S. alliance with Allergan for Paratek’s dermatology products. Previously, he was Vice President and General Manager at Teva Pharmaceuticals Industries, Ltd. (NYSE: TEVA), where he led a specialty women’s health business in Latin America, Asia, Middle East, India and Africa. Prior to Teva, he had global responsibility for Bayer Healthcare’s women’s health franchise. From 2006-2011, Mr. Bogatryrenko was at the Pfizer Women’s Health Division, where he was responsible for the cross-functional product teams in strategic planning and alliance management. He holds a MA in Foreign Language and Literature from Moscow Linguistics University and an MBA from New York University.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA™ technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company’s clinical development pipeline includes two phase 3 products. The company also manufactures and distributes branded and generic prescription prenatal vitamins as well as over-the-counter vitamins under the vitaMedMD® and BocaGreenMD® brands. More information is available at the following websites: www.therapeuticsmd.com, www.vitamedmd.com, www.vitamedmdrx.com and www.bocagreenmd.com.
This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize its hormone therapy drug candidates and obtain additional financing necessary therefor; whether the FDA will approve the company’s new drug application for its TX-004HR product candidate and whether any such approval will occur by the PDUFA date; the length, cost and uncertain results of the company’s clinical trials; the potential of adverse side effects or other safety risks that could preclude the approval of the company’s hormone therapy drug candidates; the company’s reliance on third parties to conduct its clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.